Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 8 studies | 29% ± 12% | |
oligodendrocyte | 8 studies | 24% ± 7% | |
neuron | 6 studies | 34% ± 12% | |
fibroblast | 6 studies | 22% ± 7% | |
oligodendrocyte precursor cell | 5 studies | 25% ± 3% | |
endothelial cell | 4 studies | 27% ± 7% | |
retinal ganglion cell | 4 studies | 45% ± 25% | |
hematopoietic precursor cell | 3 studies | 27% ± 9% | |
connective tissue cell | 3 studies | 26% ± 4% | |
retinal bipolar neuron | 3 studies | 17% ± 1% | |
retinal pigment epithelial cell | 3 studies | 37% ± 10% | |
type II pneumocyte | 3 studies | 35% ± 19% | |
adipocyte | 3 studies | 35% ± 22% | |
erythroblast | 3 studies | 27% ± 9% | |
glutamatergic neuron | 3 studies | 30% ± 9% | |
dendritic cell | 3 studies | 30% ± 4% | |
abnormal cell | 3 studies | 24% ± 7% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 51% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 5606.39 | 2640 / 2642 | 100% | 63.27 | 704 / 705 |
adrenal gland | 100% | 12140.04 | 258 / 258 | 97% | 32.32 | 223 / 230 |
lung | 99% | 4342.78 | 574 / 578 | 89% | 22.24 | 1028 / 1155 |
uterus | 99% | 4255.76 | 169 / 170 | 85% | 23.13 | 389 / 459 |
liver | 92% | 4566.60 | 207 / 226 | 85% | 33.10 | 344 / 406 |
prostate | 99% | 2941.10 | 242 / 245 | 75% | 10.47 | 379 / 502 |
ovary | 100% | 5215.23 | 180 / 180 | 74% | 11.51 | 317 / 430 |
bladder | 95% | 2693.52 | 20 / 21 | 73% | 15.25 | 367 / 504 |
breast | 89% | 2782.76 | 410 / 459 | 70% | 12.40 | 780 / 1118 |
skin | 62% | 4071.59 | 1123 / 1809 | 95% | 25.42 | 448 / 472 |
kidney | 73% | 1197.87 | 65 / 89 | 73% | 8.70 | 656 / 901 |
intestine | 77% | 1463.35 | 742 / 966 | 57% | 8.06 | 302 / 527 |
esophagus | 73% | 1847.27 | 1056 / 1445 | 61% | 12.97 | 111 / 183 |
stomach | 71% | 1461.68 | 256 / 359 | 57% | 7.84 | 164 / 286 |
pancreas | 44% | 561.56 | 145 / 328 | 81% | 9.88 | 145 / 178 |
thymus | 73% | 1120.14 | 474 / 653 | 35% | 2.78 | 213 / 605 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.14 | 1 / 1 |
blood vessel | 100% | 4159.41 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 4960.00 | 1199 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 20.88 | 42 / 45 |
heart | 90% | 2541.19 | 772 / 861 | 0% | 0 | 0 / 0 |
spleen | 79% | 1028.38 | 191 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 79% | 15.16 | 63 / 80 |
lymph node | 0% | 0 | 0 / 0 | 66% | 7.04 | 19 / 29 |
muscle | 50% | 2108.81 | 401 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 38% | 1279.59 | 355 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043651 | Biological process | linoleic acid metabolic process |
GO_0046456 | Biological process | icosanoid biosynthetic process |
GO_0009267 | Biological process | cellular response to starvation |
GO_0007267 | Biological process | cell-cell signaling |
GO_0008654 | Biological process | phospholipid biosynthetic process |
GO_0045595 | Biological process | regulation of cell differentiation |
GO_0036109 | Biological process | alpha-linolenic acid metabolic process |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0042759 | Biological process | long-chain fatty acid biosynthetic process |
GO_0006629 | Biological process | lipid metabolic process |
GO_0006636 | Biological process | unsaturated fatty acid biosynthetic process |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0045485 | Molecular function | omega-6 fatty acid desaturase activity |
GO_0016491 | Molecular function | oxidoreductase activity |
GO_0016717 | Molecular function | oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water |
GO_0000248 | Molecular function | C-5 sterol desaturase activity |
GO_0062076 | Molecular function | acyl-CoA delta5-desaturase activity |
GO_0016213 | Molecular function | linoleoyl-CoA desaturase activity |
Gene name | FADS1 |
Protein name | Acyl-CoA (8-3)-desaturase (EC 1.14.19.44) (Delta(5) fatty acid desaturase) (D5D) (Delta(5) desaturase) (Delta-5 desaturase) (Fatty acid desaturase 1) Fatty acid desaturase 1 |
Synonyms | hCG_40849 FADSD5 |
Description | FUNCTION: [Isoform 1]: Acts as a front-end fatty acyl-coenzyme A (CoA) desaturase that introduces a cis double bond at carbon 5 located between a preexisting double bond and the carboxyl end of the fatty acyl chain. Involved in biosynthesis of highly unsaturated fatty acids (HUFA) from the essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3) precursors. Specifically, desaturates dihomo-gamma-linoleoate (DGLA) (20:3n-6) and eicosatetraenoate (ETA) (20:4n-3) to generate arachidonate (AA) (20:4n-6) and eicosapentaenoate (EPA) (20:5n-3), respectively . As a rate limiting enzyme for DGLA (20:3n-6) and AA (20:4n-6)-derived eicosanoid biosynthesis, controls the metabolism of inflammatory lipids like prostaglandin E2, critical for efficient acute inflammatory response and maintenance of epithelium homeostasis. Contributes to membrane phospholipid biosynthesis by providing AA (20:4n-6) as a major acyl chain esterified into phospholipids. In particular, regulates phosphatidylinositol-4,5-bisphosphate levels, modulating inflammatory cytokine production in T-cells (By similarity). Also desaturates (11E)-octadecenoate (trans-vaccenoate)(18:1n-9), a metabolite in the biohydrogenation pathway of LA (18:2n-6) (By similarity). .; FUNCTION: [Isoform 2]: Does not exhibit any catalytic activity toward 20:3n-6, but it may enhance FADS2 activity. . |
Accessions | O60427 ENST00000545245.5 ENST00000542506.5 [O60427-2] F5GWE3 A0A0A0MR51 I3ZNN6 ENST00000424501.5 F5H5X5 I3ZNS6 F5H2H3 ENST00000473263.1 ENST00000539999.1 ENST00000448607.1 C9JJB3 ENST00000536991.5 F5H852 ENST00000544696.5 I3ZNL9 H7C2V0 ENST00000545405.5 H0YB97 F5GYH4 ENST00000433932.5 [O60427-2] I3ZNT3 ENST00000540767.5 ENST00000350997.12 I3ZNS3 ENST00000421879.5 F5H8G5 F5H1Q7 F5H3P6 I3ZNE3 ENST00000460649.5 I3ZNE2 ENST00000539419.5 I3ZNH3 F5H3U5 ENST00000491310.5 I3ZNL2 F5H0Y2 C9J425 ENST00000466716.5 I3ZNS1 F5H2R9 ENST00000544309.5 |